PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Stopped early · Phase 1/Phase 2

Conditions studied: Kaposi's Sarcoma

In brief

RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients with HIV-related Kaposi sarcoma.

Key facts

Study ID

NCT00686842

Run by

AIDS Malignancy Consortium

People needed

17

Starts

2008-09-01

Expected to finish

2010-12-01

Last updated by the study team

2018-06-06

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Rebecca and John Moores UCSD Cancer Center — La Jolla, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• UCLA Clinical AIDS Research and Education (CARE) Center — Los Angeles, California, United States
• Cancer Research Center of Hawaii — Honolulu, Hawaii, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
• Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.